Anheuser-Busch InBev SA/NV (NYSE:BUD) Upgraded at StockNews.com

Anheuser-Busch InBev SA/NV (NYSE:BUD) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

A number of other equities research analysts also recently issued reports on BUD. TD Cowen reduced their price objective on shares of Anheuser-Busch InBev SA/NV from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Berenberg Bank assumed coverage on shares of Anheuser-Busch InBev SA/NV in a research report on Wednesday. They set a “buy” rating on the stock. Argus upgraded shares of Anheuser-Busch InBev SA/NV from a “hold” rating to a “buy” rating and set a $70.00 price objective for the company in a research report on Thursday, March 27th. Finally, Deutsche Bank Aktiengesellschaft raised Anheuser-Busch InBev SA/NV from a “hold” rating to a “buy” rating in a report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $66.00.

Anheuser-Busch InBev SA/NV Price Performance

Shares of NYSE BUD traded up $0.86 during midday trading on Thursday, reaching $62.96. The company’s stock had a trading volume of 4,272,065 shares, compared to its average volume of 1,787,638. The company has a market cap of $113.15 billion, a P/E ratio of 19.43, a P/E/G ratio of 1.73 and a beta of 0.96. Anheuser-Busch InBev SA/NV has a fifty-two week low of $45.94 and a fifty-two week high of $67.49. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 0.69. The business’s 50 day moving average price is $57.02 and its two-hundred day moving average price is $56.83.

Anheuser-Busch InBev SA/NV (NYSE:BUD) last announced its quarterly earnings data on Wednesday, February 26th. The consumer goods maker reported $0.88 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.13. Anheuser-Busch InBev SA/NV had a return on equity of 15.29% and a net margin of 10.98%. The firm had revenue of $14.84 billion during the quarter, compared to analysts’ expectations of $14.07 billion. On average, analysts forecast that Anheuser-Busch InBev SA/NV will post 3.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Anheuser-Busch InBev SA/NV

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Thrivent Financial for Lutherans acquired a new stake in shares of Anheuser-Busch InBev SA/NV during the third quarter valued at about $220,000. Charles Schwab Investment Management Inc. boosted its position in Anheuser-Busch InBev SA/NV by 37.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 57,870 shares of the consumer goods maker’s stock worth $3,836,000 after buying an additional 15,837 shares during the period. FMR LLC boosted its position in Anheuser-Busch InBev SA/NV by 7.0% during the 3rd quarter. FMR LLC now owns 732,459 shares of the consumer goods maker’s stock worth $48,555,000 after buying an additional 47,684 shares during the period. Townsquare Capital LLC acquired a new position in Anheuser-Busch InBev SA/NV in the 3rd quarter valued at approximately $290,000. Finally, Glenmede Trust Co. NA acquired a new position in Anheuser-Busch InBev SA/NV in the 3rd quarter valued at approximately $216,000. Institutional investors own 5.53% of the company’s stock.

Anheuser-Busch InBev SA/NV Company Profile

Anheuser-Busch InBev SA/NV produces, distributes, exports, markets, and sells beer and beverages. It offers a portfolio of approximately 500 beer brands, which primarily include Budweiser, Corona, and Stella Artois; Beck's, Hoegaarden, Leffe, and Michelob Ultra; and Aguila, Antarctica, Bud Light, Brahma, Cass, Castle, Castle Lite, Cristal, Harbin, Jupiler, Modelo Especial, Quilmes, Victoria, Sedrin, and Skol brands.